Zika Vaccine Makers, 21st Century Cures Task Force Hit By Regulatory Freeze
HHS asked Federal Register Office to withdraw declaration providing liability immunity to Zika vaccine manufacturers and notice delegating authority under the Cures Act to refine the clinical trials data registry.
You may also be interested in...
‘Totality of evidence’ establishes that a manufacturer intends a drug to be used for unapproved conditions, agency says; PhRMA says final rule disregards multiple courts’ protection of free speech.
GlaxoSmithKline, NewLink Genetics and Johnson & Johnson gain protection for their candidate Ebola vaccines; NewLink teams up with Merck, and GSK prepares for Phase II/III studies in West Africa.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.